These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29112701)

  • 1. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial.
    Miles D; Im YH; Fung A; Yoo B; Knott A; Heeson S; Beattie MS; Swain SM
    Ann Oncol; 2017 Nov; 28(11):2761-2767. PubMed ID: 29112701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
    Swain SM; Kim SB; Cortés J; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Knott A; Clark E; Ross G; Benyunes MC; Baselga J
    Lancet Oncol; 2013 May; 14(6):461-71. PubMed ID: 23602601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D;
    Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
    Cortés J; Baselga J; Im YH; Im SA; Pivot X; Ross G; Clark E; Knott A; Swain SM
    Ann Oncol; 2013 Oct; 24(10):2630-2635. PubMed ID: 23868905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
    Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
    Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortés J
    Ann Oncol; 2014 Jun; 25(6):1116-21. PubMed ID: 24685829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
    Xu B; Li W; Zhang Q; Shao Z; Li Q; Wang X; Li H; Sun T; Yin Y; Zheng H; Feng J; Zhang H; Lei G; Restuccia E
    Breast Cancer Res Treat; 2020 Aug; 182(3):689-697. PubMed ID: 32564260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
    Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
    N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
    Xu B; Li W; Zhang Q; Li Q; Wang X; Li H; Sun T; Yin Y; Zheng H; Feng J; Zhu H; Siddiqui A; Macharia H; Knott A
    Breast Cancer Res Treat; 2023 Feb; 197(3):503-513. PubMed ID: 36463547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
    Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
    Debien V; Agostinetto E; Bruzzone M; Ceppi M; Martins-Branco D; Molinelli C; Jacobs F; Nader-Marta G; Lambertini M; de Azambuja E
    Clin Breast Cancer; 2024 Jul; 24(5):421-430.e3. PubMed ID: 38514306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
    Chen S; Liang Y; Feng Z; Wang M
    BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
    Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
    Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
    Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
    JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
    Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
    N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
    Miles D; Baselga J; Amadori D; Sunpaweravong P; Semiglazov V; Knott A; Clark E; Ross G; Swain SM
    Breast Cancer Res Treat; 2013 Nov; 142(1):89-99. PubMed ID: 24129974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.